Bulletin: CVS Health's Strategies To Accelerate Growth And Deleverage Should Continue Despite CEO Change; Performance Remains Good - S&P Global Ratings’ Credit Research

Bulletin: CVS Health's Strategies To Accelerate Growth And Deleverage Should Continue Despite CEO Change; Performance Remains Good

Bulletin: CVS Health's Strategies To Accelerate Growth And Deleverage Should Continue Despite CEO Change; Performance Remains Good - S&P Global Ratings’ Credit Research
Bulletin: CVS Health's Strategies To Accelerate Growth And Deleverage Should Continue Despite CEO Change; Performance Remains Good
Published Nov 06, 2020
3 pages (1284 words) — Published Nov 06, 2020
Price Free  |  Buy this Report Now

About This Report

  
Abstract:

NEW YORK (S&P Global Ratings) Nov. 6, 2020-- CVS Health Corp. (BBB/Stable/A-2) announced today the retirement of its longtime CEO Larry Merlo effective Feb. 1, 2021. He will remain on the company's board of directors through the next annual shareholder meeting in May 2021, and will serve as a strategic advisor through May 31, 2021. Karen Lynch, currently president of the health care segment (the Aetna business), will be taking over the CEO role and has been with Aetna since 2012. We continue to view CVS Health's management as a rating strength based on the team's breadth and depth, as well as overall solid track record of execution. We expect the likelihood of continued consistency in business and financial strategy

  
Report Type:

Bulletin

Ticker
Issuer
GICS
Health Care Services (35102015)
Sector
Global Issuers , Structured Finance
Country
Region
Format:
PDF Adobe Acrobat
Buy Now

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Bulletin: CVS Health's Strategies To Accelerate Growth And Deleverage Should Continue Despite CEO Change; Performance Remains Good" Nov 06, 2020. Alacra Store. May 04, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Bulletin-CVS-Health-s-Strategies-To-Accelerate-Growth-And-Deleverage-Should-Continue-Despite-CEO-Change-Performance-Remains-Good-2551154>
  
APA:
S&P Global Ratings’ Credit Research. (). Bulletin: CVS Health's Strategies To Accelerate Growth And Deleverage Should Continue Despite CEO Change; Performance Remains Good Nov 06, 2020. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Bulletin-CVS-Health-s-Strategies-To-Accelerate-Growth-And-Deleverage-Should-Continue-Despite-CEO-Change-Performance-Remains-Good-2551154>
  
Free
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Residential Mortgage-Backed Securities from one place.